Absorption and Distribution Characteristics of 5-Fluorouracil (5-FU) after an Application to the Liver Surface in Rats in
were weighed, and then liver or other tissues were homogenized in three-or two-fold volumes of their weight of pH 7.4 isotonic phosphate buffer, respectively. i.v. administration: 5-FU (10 mg/mlϫ0.5 ml) was injected into the jugular vein using a syringe with a needle (26 Gϫ 1/2Љ). Then, blood samples were collected at selected times (2, 5, 10, 15, 30, 45, 60, 90 , 120 min), and centrifuged. In addition, the liver, kidney, spleen, lung, and heart were excised at predetermined times (15, 30, 60 , 120, 180 min). In the case of application to the liver surface, the excised liver was divided into three sites and the tissues were weighed and homogenized.
5-FU Assay Procedures
The concentration of 5-FU in each tissue homogenate, plasma sample, or the solution remaining in the diffusion cell was determined by modifying reported methods. 16, 17) Briefly, the tissue homogenate, plasma sample, or solution remaining in the diffusion cell (300 ml) was added to a solution of 5-bromouracil (20 mg/ml, 150 ml) dissolved in isotonic phosphate buffer (pH 7.4) as an internal standard, 1 M sodium acetate buffer (pH 4.8, 100 ml), and 20% anhydrous sodium sulfate solution (500 ml). The mixtures were shaken with ethyl acetate (4 ml) for 10 min, and thereafter centrifuged at 900ϫg for 10 min. The organic layers (3 ml) were collected. Ethyl acetate (4 ml) was then added to the residue and the mixtures were shaken for 10 min, and thereafter centrifuged at 900ϫg for 10 min. The organic layers (4 ml) were collected and the mixed organic layers (7 ml) were evaporated. The extracted residues were dissolved in 500 ml of distilled water and washed twice with 1 ml of hexane. Samples (100 ml) were injected into the HPLC column. An HPLC system (LC-6A, Shimadzu Co., Ltd., Kyoto, Japan) with a variable-wavelength UV detector (SPD-10A, Shimadzu) was used in the reverse-phase mode. The detector wavelength, flow rate, and column temperature were set at 266 nm, 0.7 ml/min, and 25°C, respectively. The mobile phase consisted of 10 mM sodium acetate buffer (pH 4.0). The stationary phase used was a Cosmosil 5C 18 -MS-II packed column (150 mm lengthϫ4.6 mm i.d. connected with 150 mm lengthϫ4.6 mm i.d., Nacalai Tesque, Inc.).
Calculation of Moment Parameters
The plasma concentration-time profile of 5-FU until 360 min after the i.v. administration or application to the liver surface was analyzed based on the statistical moment theory. 18) Moment parameters for the plasma concentration-time profile up to 360 min (AUC plasma, 0-360 ) were calculated by numeral integration using a linear trapezoidal formula.
Statistical Analysis Statistical comparisons were performed with the unpaired Student's t-test. pϽ0.05 was considered to be statistically significant. All values were expressed as the mean valueϮstandard error (S.E.) of at least three experiments.
RESULTS AND DISCUSSION

Absorption Characteristics of 5-FU after Its Application to the Rat Liver Surface
The extent to which 5-FU was absorbed in 360 min after its application to the liver surface was calculated as 69.1% of the dose based on the amount recovered from the diffusion cell. To examine the absorption characteristics of 5-FU after its application, we studied the time course of the change in the amount of 5-FU in the diffusion cell. As shown in Fig. 1 , a semi-log plot of the amount remaining in the diffusion cell gave a straight line (correlation coefficient: r 2 ϭ0.996), indicating that the absorption of 5-FU from the liver surface proceeds via a first-order process as with the compounds in previous reports. [9] [10] [11] The absorption rate constant k a of 5-FU from the liver surface was calculated to be 0.0033 min
Ϫ1
. Previously, we have clarified that the rate of absorption from the liver surface correlated with the molecular weight of the compound. 9, 11) We compared the absorption rate of 5-FU with that of several compounds examined previously. We calculated the apparent permeability coefficient, P app (mm/min), of several compounds after their application to the liver surface, according to the following Eq. 1. (1) Where V a is the application volume of drug solution, and A cell is the application area of the diffusion cell.
Also, the following equation has been proposed with respect to drug absorption from the gastrointestinal mucosa via passive diffusion 19, 20) : (2) P a represents the partition coefficient and constants A and B are the correction factor to P a and constant for diffusion, respectively. Because each compound is highly hydrophilic, the righthand side of Eq. 2 can be transformed as a fixed number. Then, based on Eq. 2, we plotted P app against the reciprocal of the square root of the molecular weight (1/√ --MW) of compounds with different molecular weights and 5-FU (Fig. 2) . As shown in Fig. 2 , a linear relationship was observed between the P app and 1/√ --MW of several compounds including 5-FU (correlation coefficient: r 2 ϭ0.949) although there is a little difference. The estimated P app value of 5-FU (22.9 mm/ min) was in good agreement with the experimental value (25.8 mm/min).
Systemic Distribution of 5-FU after Application to the Rat Liver Surface It was reported that the systemic distribution and toxicity of 5-FU varied with the administration route. [21] [22] [23] [24] In the case of hepatic arterial infusion, hepatic extraction of anticancer drugs resulted in minimal systemic exposure, potentially minimizing systemic side effect. 25) Then, we examined the systemic distribution of 5-FU after its application to the rat liver surface. Figures 3A and B show the plasma concentration profiles of 5-FU after an i.v. administration or liver surface application, respectively. After the i.v. administration, 5-FU was rapidly eliminated from the plasma and could not be detected at 120 min (Fig. 3A) . After the application of 5-FU to the liver surface, on the other hand, low plasma concentrations (Ͻ1.2 mg/ml) were observed until 360 min (Fig. 3B) . The AUC plasma of 5-FU was calculated as representative of systemic drug exposure. The AUC plasma after application to the liver surface (306.6Ϯ24.9 mg · min/ml) was significantly smaller than that after i.v. administration (406.3Ϯ15.2 mg · min/ml). 5-FU is catabolised by dihydropyrimidine dehydrogenase, the ratelimiting enzyme that bring about first pass effect of 5-FU, in the liver. Also, the hepatic extraction ratio of 5-FU was reported to be higher than about 90%. 26) We considered that the clearance from the liver of 5-FU after application to liver surface is the metabolism in the liver. It would appear that the systemic drainage of 5-FU was suppressed by the hepatic extraction after the application to the liver surface. Figures 4A and B illustrate the concentration profiles of 5-FU in the liver, kidney, spleen, lung, and heart until 180 min after i.v. administration or until 360 min after application to the liver surface of 5-FU, respectively. After i.v. administration, 5-FU mainly distributed in the kidney, and the concentration in the liver was significantly lower than that in kidney, spleen or heart at 15 min and could not be detected thereafter (Fig. 4A) . Also, the concentrations of 5-FU at the three sites of the liver were almost the same at 15 min after i.v. administration (data not shown). After its application to the liver surface, on the other hand, 5-FU was preferentially distributed at site 1, and was not detected at the other sites or in other tissues (Fig. 4B) . Therefore, these results suggest that the application of 5-FU to the liver surface suppressed drainage into the systemic circulation and other tissues, potentially minimizing the systemic side effect. However, further studies are necessary for us to investigate the possibility of accumulation to the liver tumor cells in tumor-bearing rats because distribution of 5-FU to tumor should be the most important issue for clinical application.
In conclusion, we have demonstrated that 5-FU was absorbed from the surface of the liver in rats according to a first-order process and the absorption rate could be estimated from the molecular weight. Also, the 5-FU applied to the liver surface was preferentially distributed at site 1 and the plasma concentration of 5-FU was low until 360 min. These results suggested the possibility of reducing the systemic side effects of 5-FU by applying it to the liver surface. 
